Bioage Labs Stock Analysis
| BIOA Stock | 20.73 0.75 3.75% |
BioAge Labs has over 8.7 Million in debt which may indicate that it relies heavily on debt financing. At present, BioAge Labs' Short Term Debt is projected to increase significantly based on the last few years of reporting. The current year's Long Term Debt is expected to grow to about 4.8 M, whereas Short and Long Term Debt Total is forecasted to decline to about 7.4 M. With a high degree of financial leverage come high-interest payments, which usually reduce BioAge Labs' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
BioAge Labs' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BioAge Labs' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BioAge Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect BioAge Labs' stakeholders.
For many companies, including BioAge Labs, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BioAge Labs, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BioAge Labs' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 3.1179 | Price Sales 146.2783 | Shares Float 27.7 M | Wall Street Target Price 15.6667 | Earnings Share 13.61 |
BioAge Labs is overvalued with Real Value of 15.19 and Target Price of 15.67. The main objective of BioAge Labs stock analysis is to determine its intrinsic value, which is an estimate of what BioAge Labs is worth, separate from its market price. There are two main types of BioAge Labs' stock analysis: fundamental analysis and technical analysis.
The BioAge Labs stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioAge Labs' ongoing operational relationships across important fundamental and technical indicators.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. BioAge Stock Analysis Notes
About 59.0% of the company shares are held by institutions such as insurance companies. The book value of BioAge Labs was currently reported as 7.74. The company recorded earning per share (EPS) of 13.61. BioAge Labs had not issued any dividends in recent years. BioAmber Inc., an industrial biotechnology company, produces and sells renewable chemicals worldwide. BioAmber Inc. was founded in 2008 is headquartered in Montreal, Canada. BioAmber operates under Chemicals classification in USA and traded on OTC Market. It employs 85 people. For more info on BioAge Labs please contact Kristen Fortney at 510 806 1445 or go to https://bioagelabs.com.BioAge Labs Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. BioAge Labs' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding BioAge Labs or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| BioAge Labs is way too risky over 90 days horizon | |
| BioAge Labs appears to be risky and price may revert if volatility continues | |
| BioAge Labs has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (71.11 M) with loss before overhead, payroll, taxes, and interest of (3.74 M). | |
| BioAge Labs currently holds about 4.63 M in cash with (51.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| BioAge Labs has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Morgan Stanley Boosts Price Target on BioAge Labs to 23 From 12, Keeps Equalweight Rating - marketscreener.com |
BioAge Largest EPS Surprises
Earnings surprises can significantly impact BioAge Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-06 | 2025-03-31 | -0.5276 | -0.36 | 0.1676 | 31 | ||
2025-08-06 | 2025-06-30 | -0.3814 | -0.6 | -0.2186 | 57 | ||
2025-03-20 | 2024-12-31 | -0.655 | -1.0 | -0.345 | 52 |
BioAge Labs Environmental, Social, and Governance (ESG) Scores
BioAge Labs' ESG score is a quantitative measure that evaluates BioAge Labs' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BioAge Labs' operations that may have significant financial implications and affect BioAge Labs' stock price as well as guide investors towards more socially responsible investments.
BioAge Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 865.53 M.BioAge Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.25) | (0.24) |
Management Efficiency
BioAge Labs has return on total asset (ROA) of (0.1746) % which means that it has lost $0.1746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2564) %, meaning that it created substantial loss on money invested by shareholders. BioAge Labs' management efficiency ratios could be used to measure how well BioAge Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of February 10, 2026, Return On Tangible Assets is expected to decline to -0.19. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, BioAge Labs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Non Current Assets Total are forecasted to decline to about 967 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 27.11 | 28.47 | |
| Tangible Book Value Per Share | 27.11 | 28.47 | |
| Enterprise Value Over EBITDA | 3.72 | 3.91 | |
| Price Book Value Ratio | 0.17 | 0.18 | |
| Enterprise Value Multiple | 3.72 | 3.91 | |
| Price Fair Value | 0.17 | 0.18 | |
| Enterprise Value | 151.5 M | 111.9 M |
The management team at BioAge Labs has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Technical Drivers
As of the 10th of February, BioAge Labs shows the Risk Adjusted Performance of 0.2323, mean deviation of 4.41, and Downside Deviation of 3.45. BioAge Labs technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioAge Labs Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in BioAge Labs price series with the more recent values given greater weights.
BioAge Labs Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAge Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAge Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAge Labs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioAge Labs Outstanding Bonds
BioAge Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioAge Labs uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioAge bonds can be classified according to their maturity, which is the date when BioAge Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BioAge Labs Predictive Daily Indicators
BioAge Labs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioAge Labs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioAge Labs Corporate Filings
F4 | 3rd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 22nd of January 2026 Other Reports | ViewVerify | |
F4 | 21st of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
BioAge Labs Forecast Models
BioAge Labs' time-series forecasting models are one of many BioAge Labs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAge Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BioAge Labs Bond Ratings
BioAge Labs financial ratings play a critical role in determining how much BioAge Labs have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BioAge Labs' borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (5.41) | Unlikely Manipulator | View |
BioAge Labs Debt to Cash Allocation
As BioAge Labs follows its natural business cycle, the capital allocation decisions will not magically go away. BioAge Labs' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
BioAge Labs currently holds 8.7 M in liabilities with Debt to Equity (D/E) ratio of 172.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioAge Labs has a current ratio of 1.32, which is within standard range for the sector. Note, when we think about BioAge Labs' use of debt, we should always consider it together with its cash and equity.BioAge Labs Total Assets Over Time
BioAge Labs Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BioAge Labs uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BioAge Labs Debt Ratio | 2.65 |
BioAge Labs Corporate Bonds Issued
Most BioAge bonds can be classified according to their maturity, which is the date when BioAge Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BioAge Short Long Term Debt Total
Short Long Term Debt Total |
|
About BioAge Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioAge Labs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioAge shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioAge Labs. By using and applying BioAge Stock analysis, traders can create a robust methodology for identifying BioAge entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current BioAge Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioAge analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioAge analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 15.67 | Hold | 4 | Odds |
Most BioAge analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioAge stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioAge Labs, talking to its executives and customers, or listening to BioAge conference calls.
BioAge Stock Analysis Indicators
BioAge Labs stock analysis indicators help investors evaluate how BioAge Labs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioAge Labs shares will generate the highest return on investment. By understating and applying BioAge Labs stock analysis, traders can identify BioAge Labs position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 25 M | |
| Total Stockholder Equity | 323.1 M | |
| Net Borrowings | -6 M | |
| Capital Lease Obligations | 202 K | |
| Property Plant And Equipment Net | 791 K | |
| Cash And Short Term Investments | 354.3 M | |
| Cash | 354.3 M | |
| 50 Day M A | 15.1924 | |
| Net Interest Income | 7.3 M | |
| Total Current Liabilities | 27.8 M | |
| Investments | -366 K | |
| Interest Expense | 2.4 M | |
| Stock Based Compensation | 7 M | |
| Long Term Debt | 2.5 M | |
| Common Stock Shares Outstanding | 10.7 M | |
| Total Cashflows From Investing Activities | -366 K | |
| Free Cash Flow | -51.9 M | |
| Other Current Assets | 2.8 M | |
| Accounts Payable | 2 M | |
| Net Debt | -345.6 M | |
| Other Operating Expenses | 78.2 M | |
| Non Current Assets Total | 1.1 M | |
| Liabilities And Stockholders Equity | 358.2 M | |
| Non Currrent Assets Other | 240 K |
Complementary Tools for BioAge Stock analysis
When running BioAge Labs' price analysis, check to measure BioAge Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAge Labs is operating at the current time. Most of BioAge Labs' value examination focuses on studying past and present price action to predict the probability of BioAge Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAge Labs' price. Additionally, you may evaluate how the addition of BioAge Labs to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |